Anna Nowicka

Anna Nowicka

Auto-generated profile, based on publicly available information

Anna Nowicka

First Department of Infectious Diseases, J. Gromkowski Regional Specialist Hospital, Wroclaw, Poland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in International Journal of Hepatology
Verified
Journal Article
Open access
ANAnna A. Nowicka
Anna A. Nowicka
AGAgnieszka Gomulkiewicz
Agnieszka Gomulkiewicz
SSSylwia Serafińska
Sylwia Serafińska
KSKrzysztof Simon
Krzysztof Simon
Piotr DziegielPiotr Dziegiel
Piotr Dziegiel
Metallothioneins (MTs) are primarily known for maintaining cellular metal homeostasis and protecting against metal toxicity, but they also play critical roles in mitigating oxidative stress and modulating immune responses. Reduced MTs expression is associated with disease progression in several chronic hepatic disorders. In metabolic dysfunction–associated steatotic liver disease (MASLD), MT1 downregulation has been linked to the transition from simple steatosis to steatohepatitis. Additionally, evidence suggests that individuals with low MTs expression may be more susceptible to obesity, which is one of the key drivers in the development of MASLD. In chronic viral hepatitis, in vivo MTs downregulation contrasts with acute‐phase in vitro upregulation, suggesting an effect of persistent inflammation. MTs downregulation in hepatocellular carcinoma (HCC) correlates with poor prognosis, positioning MTs as potential biomarkers and therapeutic targets. In contrast, increased MTs expression may play a protective or diagnostically informative role in other conditions. In alcoholic hepatitis, MT1 overexpression contributes to defense against oxidative stress and inflammation. In Wilson’s disease, MTs demonstrates prominent hepatic expression and may offer diagnostic value alongside traditional markers such as rhodanine staining. In cholestatic liver diseases like PBC and PSC, MTs expression correlates with disease progression. This review highlights the emerging role of MTs in liver disease pathogenesis and positions them as promising molecular tools that may inform future strategies for diagnosis, prognosis, and treatment of liver diseases.

22 October 2024 in Archives of Medical Science
Verified
Journal Article
Open access
DHDepartment of Infectoius Disease and Hepatology
Department of Infectoius Disease and Hepatology
ASAnna Szymanek-Pasternak
Anna Szymanek-Pasternak
JGJoanna Górka-Dynysiewicz
Joanna Górka-Dynysiewicz
ANAnna Nowicka
Anna Nowicka
KSKrzysztof Simon
Krzysztof Simon
Michael KuklaMichael Kukla
Michael Kukla
Introduction: The aim of the study was to evaluate chemerin levels as a potentially useful marker in diagnosing early-stage hepatocellular carcinoma (HCC) as well as in HCC staging.Material and methods: The cohort comprised 76 patients: 45 people with cirrhosis and HCC (including 13 with a single HCC lesion in the liver and 32 with metastatic lesions/spread of HCC in the liver) and 21 people with isolated cirrhosis. The control group included 10 clinically healthy people.Results: The degree of liver failure in the whole cohort was assessed using the Child-Turcotte-Pugh (CTP) score (class A – 34, class B – 28, class C – 4) and using the MELD score (≤ 12 points – 45 and > 12 points – 21 people). Serum chemerin level in patients with liver cirrhosis only was 53.30 ng/ml, in patients with a single HCC lesion 77.01 ng/ml, and in patients with disseminated HCC 83.58 ng/ml. In the control group, the chemerin level was 82.20 µg/ml. When patients with cirrhosis and with/without HCC were divided according to their CTP scores, the level of chemerin was as follows: class A – 83.90 µg/ml, class B – 61 µg/ml, class C – 30.10 µg/ml. For MELD scores ≤ and > 12 it was 75 µg/ml and 58 µg/ml, respectively. For BCLC staging the results were as follows: A – 20.10 µg/ml, B – 20.20 µg/ml, C –19.44 µg/ml.Conclusions: Chemerin increases with the number of neoplastic lesions and decreases with the progression of liver failure as assessed using the CTP score.

1 December 2024 in International Medical Case Reports Journal
Verified
Journal Article
Open access
ANAnna Nowicka
Anna Nowicka
ASAnna Szymanek-Pasternak
Anna Szymanek-Pasternak
JJJustyna Janocha-Litwin
Justyna Janocha-Litwin
KSKrzysztof Simon
Krzysztof Simon
Hepatitis B virus (HBV) reactivation is a recognized complication of long-term immunosuppressive or cytotoxic therapy, typically occurring during immunosuppression or within a few months after treatment. To mitigate this risk, hepatological societies recommend the use of nucleos(t)ide analogues (NA) for HBV reactivation prophylaxis, along with post-treatment monitoring; though, these recommendations are not universally consistent across different guidelines. We present a case of late HBV reactivation in a 76year-old male with occult HBV infection who received rituximab-based therapy for chronic lymphocytic leukemia. In accordance with HBV reactivation guidelines, the patient was prescribed entecavir 0.5 mg daily during chemotherapy and for 18 months following the completion of hematological treatment. Despite adherence to these recommendations, the patient developed HBV reactivation 2 years and 5 months after the cessation of rituximab-based therapy, which progressed to acute HBV hepatitis. Our case emphasizes the need for extended follow-up in patients undergoing rituximab-based immunosuppression. It highlights the critical importance of vigilance for HBV reactivation and the potential consequences of delayed treatment. This case supports evidence on the unpredictability of HBV reactivation timelines and underscores the need for standardized monitoring protocols.

19 September 2025 in JMIR Preprints
Verified
Preprint
Open access
MMMaria Marecka
Maria Marecka
ANAnna Nowicka
Anna Nowicka
ASAleksandra Suwińska
Aleksandra Suwińska
POPiotr Orzechowski
Piotr Orzechowski
BACKGROUND Virtual clinical triage is central to digital front door strategies, yet how interaction mode—structured, closed-ended AI questionnaires vs large language model (LLM)–enabled conversational dialogue—affects information capture, engagement, and alignment with care recommendations is unclear. OBJECTIVE This study compared demographics, clinical content, engagement, and alignment with recommended care between a traditional, structured questionnaire interface (traditional triage [TT]) and an LLM-enabled conversational interface (conversational triage [CT]) sharing the same validated Bayesian reasoning engine. METHODS This comparative, retrospective observational study analyzed 116,890 encounters over 28 weeks (January 2025 to August 2025) completed on a virtual triage website. Users self-selected TT or CT. Primary end points included demographic and clinical characteristics, engagement patterns, and self-reported intended adherence to triage recommendations. Analyses used poststratification weighting by age and sex. Group differences were assessed with the chi-square test (with Rao-Scott correction for weighted data) and survey-weighted Wilcoxon rank-sum test; P values for comparisons of proportions were adjusted for multiple comparisons using the Benjamini-Hochberg false discovery rate procedure. For CT, opening and closing sentiment (positive, neutral, or negative) was labeled using a prompt in Gemini 2.5 Flash. RESULTS Of 116,890 respondents, 100,533 (86%) used TT and 16,357 (14%) used CT. Female users were the majority in both groups but less predominant in CT (10,402/16,357, 64% vs 71,039/100,533, 71%) than in TT. TT users skewed younger (aged 18-29 years >50%), whereas CT was more evenly distributed with higher shares at ages 12 to 17, 30 to 44, and ≥45 years. Median session duration was longer with CT than with TT (8 minutes 21 seconds, IQR 6 minutes 10 seconds to 11 minutes 51 seconds vs 4 minutes 25 seconds, IQR 3 minutes 14 seconds to 6 minutes 22 seconds, respectively). CT elicited more clinical findings (median 36, IQR 31-43 vs 32, IQR 27-38; P<.001) and surfaced more mental health evidence (eg, depressive symptoms, 8.5% vs 6.2%; P<.001). Posttriage intent survey completion was higher with CT (5104/16,357, 31.2% vs 5968/100,533, 5.9%). Self-reported intended adherence to the recommended level of care was higher with CT (1749/5104, 34.3% vs 1740/5968, 29.2%; P<.001), especially at extremes of acuity: self-care (534/625, 85.4% vs 325/525, 61.9%), emergency room (171/723, 23.7% vs 100/949, 10.5%), and ambulance (39/339, 11.5% vs 27/554, 4.9%; all P<.001). Among CT encounters, positive sentiment increased markedly, while negative sentiment rose slightly. CONCLUSIONS The LLM-enabled CT was used by a more demographically diverse user base and was associated with richer clinical context, deeper engagement, and higher self-reported intended adherence among survey respondents, particularly for low-acuity self-care and high-acuity emergency scenarios, where reassurance or urgent escalation is critical. This highlights the potential of hybrid LLM tools that integrate validated clinical logic to support engagement, information gathering, and care navigation in digital front door settings.

30 October 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
KSKrzysztof Simon
Krzysztof Simon
JJJustyna Janocha-Litwin
Justyna Janocha-Litwin
ANAnna Nowicka
Anna Nowicka
ASAnna Szymanek-Pasternak
Anna Szymanek-Pasternak
SSSylwia Beata Serafińska
Sylwia Beata Serafińska
DHDepartment of Infectoius Disease and Hepatology
Department of Infectoius Disease and Hepatology
To date, SARS Cov-2 virus has caused more than 775 million cases worldwide and led to 7 million deaths. The virus enters cells with the aid of the ACE2 receptor located in the airway epithelium, but also in endothelial cells lining the inner walls of vessels. Endothelial damage results in impaired blood flow and gas exchange. Statins have been shown to have a pleiotropic effects on the vascular epithelium. Aim of the study: Assessment of the efficacy and safety of statin therapy in patients with COVID-19. Methods: Two hundred and one COVID-19 patients hospitalized at the Jerzy Gromkowski Regional Specialist Hospital between March 2020 and December 2021 (i.e. during the period dominated by Alpha, Beta, Gamma and Delta variants). Patients were divided into three groups: (I) patients treated with statins prior to the admission to the hospital; (II) patients started on statins after admission due to Covid-19; (III) control patients with Covid-19, not treated with statins either prior to or during hospitalization. Met Statistica 13.1 calculations were used in the paper. Shapiro-Wilk, Kruskal-Wallis and ANOVA tests were also performed. Results: Out of the 201 patients total, group I comprised 66 patients with a mean age of 66.2 years; group II comprised 33 patients with a mean age of 75.3 years; and the control group comprised 97 patients with a mean age of 61.1 years. The groups characteristics did not show significant differences in terms of gender, place of hospitalization, percentage of Covid-19 vaccinations, number of convalescents. Death was observed in: 12% of patients in group I, 6% of patients in group II, and 6% of patients in group III. Body Mass Index (BMI) in group I was 31.3: a value significantly higher than the control group’s 28.3, (p<0.05). The severity of Covid-19 assessed on admission in group I – 4.09 – was statistically higher than in the control group 3.52 (p<0.05). The number of pulmonary embolism incidents did not differ between groups. Conclusions: During the period dominated by Alpha, Beta, Gamma and then Delta variants, we found no statistically significant positive or negative effects of statin therapy on the duration of hospitalization, number of complications or percentage of deaths between the two studied groups of patients: those who received statins prior to hospitalization, and those who received statins during hospitalization.

22 September 2026 in JMIR AI
Verified
Journal Article
Open access
MMMaria Marecka
Maria Marecka
ANAnna Nowicka
Anna Nowicka
ASAleksandra Suwińska
Aleksandra Suwińska
POPiotr Orzechowski
Piotr Orzechowski
Background: Virtual clinical triage is central to digital front door strategies, yet how interaction mode—structured, closed-ended AI questionnaires vs large language model (LLM)–enabled conversational dialogue—affects information capture, engagement, and alignment with care recommendations is unclear. Objective: This study compared demographics, clinical content, engagement, and alignment with recommended care between a traditional, structured questionnaire interface (traditional triage [TT]) and an LLM-enabled conversational interface (conversational triage [CT]) sharing the same validated Bayesian reasoning engine. Methods: This comparative, retrospective observational study analyzed 116,890 encounters over 28 weeks (January 2025 to August 2025) completed on a virtual triage website. Users self-selected TT or CT. Primary end points included demographic and clinical characteristics, engagement patterns, and self-reported intended adherence to triage recommendations. Analyses used poststratification weighting by age and sex. Group differences were assessed with the chi-square test (with Rao-Scott correction for weighted data) and survey-weighted Wilcoxon rank-sum test; P values for comparisons of proportions were adjusted for multiple comparisons using the Benjamini-Hochberg false discovery rate procedure. For CT, opening and closing sentiment (positive, neutral, or negative) was labeled using a prompt in Gemini 2.5 Flash. Results: Of 116,890 respondents, 100,533 (86%) used TT and 16,357 (14%) used CT. Female users were the majority in both groups but less predominant in CT (10,402/16,357, 64% vs 71,039/100,533, 71%) than in TT. TT users skewed younger (aged 18-29 years >50%), whereas CT was more evenly distributed with higher shares at ages 12 to 17, 30 to 44, and ≥45 years. Median session duration was longer with CT than with TT (8 minutes 21 seconds, IQR 6 minutes 10 seconds to 11 minutes 51 seconds vs 4 minutes 25 seconds, IQR 3 minutes 14 seconds to 6 minutes 22 seconds, respectively). CT elicited more clinical findings (median 36, IQR 31-43 vs 32, IQR 27-38; P<.001) and surfaced more mental health evidence (eg, depressive symptoms, 8.5% vs 6.2%; P<.001). Posttriage intent survey completion was higher with CT (5104/16,357, 31.2% vs 5968/100,533, 5.9%). Self-reported intended adherence to the recommended level of care was higher with CT (1749/5104, 34.3% vs 1740/5968, 29.2%; P<.001), especially at extremes of acuity: self-care (534/625, 85.4% vs 325/525, 61.9%), emergency room (171/723, 23.7% vs 100/949, 10.5%), and ambulance (39/339, 11.5% vs 27/554, 4.9%; all P<.001). Among CT encounters, positive sentiment increased markedly, while negative sentiment rose slightly. Conclusions: The LLM-enabled CT was used by a more demographically diverse user base and was associated with richer clinical context, deeper engagement, and higher self-reported intended adherence among survey respondents, particularly for low-acuity self-care and high-acuity emergency scenarios, where reassurance or urgent escalation is critical. This highlights the potential of hybrid LLM tools that integrate validated clinical logic to support engagement, information gathering, and care navigation in digital front door settings.